CN1205950C - Sanweishenxue capsule for treating aplastic anemia and its preparation technology - Google Patents
Sanweishenxue capsule for treating aplastic anemia and its preparation technology Download PDFInfo
- Publication number
- CN1205950C CN1205950C CNB02114687XA CN02114687A CN1205950C CN 1205950 C CN1205950 C CN 1205950C CN B02114687X A CNB02114687X A CN B02114687XA CN 02114687 A CN02114687 A CN 02114687A CN 1205950 C CN1205950 C CN 1205950C
- Authority
- CN
- China
- Prior art keywords
- aplastic anemia
- powder
- radix ginseng
- capsule
- venenum bufonis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a capsule which comprises three medicines including ginseng and spatholobus stem and is used for curing aplastic anemia, and preparation technology thereof. The present invention provides a pure Chinese medicine for curing aplastic anemia. The medicine is prepared by combining dry general panaxoside powder, spatholobus paste powder and dry toad venom powder, wherein the dry general panaxoside powder is extracted from three Chinese medical materials of ginseng, spatholobus and toad venom. The preparation technology can be approximately divided into technology flows of Chinese medicine preparation, processing, extraction, parching, pulverization, sifting, uniform mixing, encapsulation, etc. The preparation technology is simple. The patent medical preparation can effectively improve the deficiency of patients's hemopoietic stem cells, restore the hematopoietic function, promote medullary hematopoietic tissues and fat tissues have balance proportion, and rapidly control and cure infectious diseases. Simultaneously, the medicine has curative effect on complicating diseases, treats both the manifestation and the root cause of diseases, chronically relieves aplastic anemia until recovery, has short curative period, high curative effect and no toxic or side effect, and has specially good effect on chronic aplastic anemia.
Description
Affiliated technical field
The present invention treats aplastic anemia capsule and preparation technology thereof and belongs to special for treating and improve because of the peripheral blood hemoglobin content is lower than medicine and preparation technology thereof in the caused Anemia of lower limits of normal, relates in particular to a kind of medicinal preparation for oral administration and preparation technology thereof of pure treatment by Chinese herbs aplastic anemia.
Background technology
Chinese medicine commonly used is Colla cornus cervi, Rhizoma Curculiginis, Herba Epimedii, the Radix Astragali, gives birth to Radix Rehmanniae Preparata, the Radix Polygoni Multiflori, Radix Angelicae Sinensis, Herba Cistanches, crust halberd, Fructus Psoraleae, Semen Cuscutae, Fructus Lycii, Colla Corii Asini etc. in the Chinese medicine preparation of treatment aplastic anemia at present.State's internal therapy chronic aplastic anemia androgen commonly used merges the treatment of traditional Chinese medical science the kidney invigorating method.Above-mentioned Chinese medicine and preparation are this with the kidney invigorating, double benefiting QI for activating blood circulation, but acute aplastic anemia often reaches main performance with hemorrhage and infectious fever for first, infect and hemorrhage reciprocal causation, even chronic aplastic anemia also is to be first and main performance with anemia, being limited to mucocutaneous hemorrhage more, but also accompanying infection, often based on respiratory infection diseases, all be that Different types of etiopathogenises causes hematopoietic stem cell and hematopoieticmicroenviron-ment damage, cause the red bone marrow total capacity to reduce generation with fatty marrow, hemopoietic depletion, pancytopenia.Most of patients is often with having a delicate constitution, the neurasthenia, sexual function is low, hepatitis, nephritis, glycosuria disease, diseases such as laryngopharynx swelling and pain, and tonify Qi of the kidney, medicine only can prevent renal failure and avoids the generation of Anemia among invigorating blood circulation, very little to the aplastic anemia curative effect of disease, especially the androgens medicine must competence exertion effect on certain remaining hematopoietic stem cell basis, to acute and serious aplastic anemia Chang Wuxiao, though chronic aplastic anemia is had certain curative effect, but it is big that dosage is not only wanted, the SM time also will be grown, the course of treatment is more than at least 6 months, and easily produce adverse side effect, and the part patient produces dependency to androgen, and relapse rate is higher after the drug withdrawal.
Summary of the invention
Merge the deficiency of the humble and easy generation of the kidney invigorating method curative effect of medication adverse side effect in order to overcome existing treatment aplastic anemia Chinese medicine preparation and androgen with Chinese medicine, the present invention treats aplastic anemia capsule and preparation technology thereof provides reasonable, each the prescription medicament complementary action of filling a prescription remarkable, oral pharmaceutical preparations easily again to Patients with Aplastic Anemia.Not only technology is easy for preparation treatment aplastic anemia capsule, and the quantitative science of all medicines of filling a prescription is accurate, in an orderly manner uniform mixing, after the patient takes, treating both the principal and secondary aspects of a disease, the damage of hematopoietic stem cell and hematopoieticmicroenviron-ment can be restored rapidly and improve, and the qi-supplementing, blood-engendering ability is strengthened, simultaneously by detoxifcation, pain relieving, eliminate respiratory tract infectious condition of illness rapidly, accelerate concurrent treatment of conditions, impel patient's red bone marrow total capacity to increase, hemopoietic is vigorous again, gets well very soon.
In order to realize the foregoing invention purpose, the present invention treats the aplastic anemia capsule and technical scheme that preparation technology adopted is: treatment aplastic anemia capsule is made up of Radix Ginseng total saponins dry powder 12.5%, Spatholobi Paste powder 85.0%, Venenum Bufonis dry powder 2.5% side of closing that Radix Ginseng, Caulis Spatholobi, Venenum Bufonis three flavor Chinese crude drugs extract, with above-mentioned Chinese crude drug concoct respectively be processed into extract dry powder after, elder generation is with Venenum Bufonis dry powder and the abundant mixing of Radix Ginseng total saponins dry powder during mixing, again with Spatholobi Paste powder mix homogeneously, No. 1 capsule of packing into promptly gets patent medicine, and is oral for the patient.The present invention treats in the aplastic anemia capsule prescription, and Radix Ginseng total saponins has the metabolic function of rising blood pressure, stabilizing blood pressure and promotion sugar, to have a delicate constitution, neurasthenia, sexual function are low, chronic hepatitis, chronic nephritis, diabetes etc. have better curative effect; The Spatholobi Paste powder can make hemocyte increase and the hemoglobin rising, have enrich blood, promoting the circulation of blood, dredge the meridian passage effect; Venenum Bufonis has detoxifcation, pain-relieving functions, can eliminate infectious conditions, and especially the respiratory infection diseases curative effect to concurrent is rapid.Three flavor prescription medicines have complementary functions, collaborative invigorating QI and blood, detoxifcation, the analgesic effect of reaching.The beneficial effect that the present invention treats aplastic anemia capsule and preparation technology thereof is: in curing mainly aplastic anemia, can improve the hematopoietic stem cell defective effectively, recover the normal hematopoiesis function, impel bone marrow hematogenesis tissue and fatty tissue ratio balance, and control and treat infectious disease rapidly, simultaneously to have a delicate constitution, complication generation curative effect such as neurasthenia, sexual function are low, chronic hepatitis, chronic nephritis, diabetes, treating both the principal and secondary aspects of a disease makes the patient obtain long-term remission so that recovery from illness.The present invention treats the aplastic anemia capsule has specially good effect to chronic aplastic anemia.
The specific embodiment
The best effectively prescription amount of each prescription in the treatment aplastic anemia capsule, effectively degree is as shown in the table:
Group medicine title | Formula ratio (gram) | Content (%) |
Radix Ginseng total saponins dry powder | 125 | 12.5 |
The Spatholobi Paste powder | 850 | 85.0 |
Venenum Bufonis dry powder | 25 | 2.5 |
Add up to | 1000 | 100.0 |
2. treat the aplastic anemia capsules preparation technique:
1. Radix Ginseng total saponins dry powder is produced.At first Radix Ginseng is scrubbed and soaked and float, remove impurity, and at pressure 0.5kg/cm
2Under 110.8 ℃ of conditions of temperature, steam 10 minutes, fresh ginseng is concocted be processed into Radix Ginseng Rubra; With Radix Ginseng Rubra is ultra-thin be cut into thickness and be 0.1mm, diameter 1.5cm left and right sides thin slice after, extract seven times with 65% (20 ℃) alcohol heating reflux, merge extractive liquid, also filters, and after recovery ethanol concentrates, adds 95% ethanol, place precipitation filtered in 24 hours, it is concentrated that filtrate is placed precipitation filtration back recovery in 24 hours ethanol again with 40%NaOH liquid adjusting pH value to 8.0, handles 3 times in accordance with the law, is condensed into Radix Ginseng extractum, drying became Radix Ginseng total saponins dry powder after pulverizing 40 mesh sieves, and weighing is standby.
2. the Spatholobi Paste powder is produced.Select decocting twice after first-class Caulis Spatholobi (spatholobus suberectus rattan) roguing for use, 4 hours for the first time, 2 hours for the second time, merge decocting liquid twice, be concentrated into proportion 1.2 and promptly get the Caulis Spatholobi soft extracts, drying is pulverized one-tenth Spatholobi Paste powder behind 40 mesh sieves, and weighing is standby.
3. Venenum Bufonis dry powder is produced.Catch Venenum Bufonis in summer, Qiu Erji, clean, squeeze the white serosity of getting ear rear gland and glandular integumentaria, after the filtration roguing, select for use 95% alcohol heating reflux to extract the solid, shaped Venenum Bufonis, become Venenum Bufonis dry powder after fresh milk immersion after drying is pulverized, crossed 40 mesh sieves, weighing is standby.
4. capsule preparation.Earlier with behind Venenum Bufonis dry powder and the abundant mix homogeneously of Radix Ginseng total saponins dry powder again with Spatholobi Paste powder mix homogeneously, the capsule of packing into No. 1 promptly gets 5000 patent medicine.
3. treat aplastic anemia capsule instructions of taking and consumption:
Oral for the patient; Be grown up 3 times on the one, 2~3 of every days, the child reduces by half.
Claims (2)
1. treatment aplastic anemia capsule is characterized in that the Spatholobi Paste powder 85.0% that raw material extracts from Caulis Spatholobi by the Radix Ginseng total saponins dry powder 12.5% that extracts with seven heating reflux methods of 65% ethanol, with twice decocting method, Venenum Bufonis dry powder 2.5% side of closing that extracts with 95% alcohol heat reflux method form from Venenum Bufonis from the Radix Ginseng Rubra decoction pieces.
2. the capsular preparation technology of treatment aplastic anemia as claimed in claim 1, it is characterized in that the Radix Ginseng Rubra decoction pieces that Radix Ginseng is steamed processing extracts seven times with 65% alcohol heating reflux, merge extractive liquid, filters, reclaim the concentrated back of ethanol and add the filtration in 24 hours of 95% ethanol placement precipitation, it is concentrated that filtrate is placed precipitation filtration back recovery in 24 hours ethanol again with 40%NaOH liquid adjusting pH value to 8.0, handle 3 times in accordance with the law, be condensed into Radix Ginseng extractum, drying became Radix Ginseng total saponins dry powder after pulverizing 40 mesh sieves, and was standby by the prescription weighing; Select decocting twice after the first-class Caulis Spatholobi roguing for use, 4 hours for the first time, 2 hours for the second time, merge decocting liquid twice, be concentrated into proportion 1.2 soft extracts, drying becomes the Spatholobi Paste powder after pulverizing 40 mesh sieves, and is standby by the prescription weighing; Catch Venenum Bufonis in summer, Qiu Erji, clean, squeeze the white serosity of getting ear rear gland and glandular integumentaria, after filtering roguing, extract the solid, shaped Venenum Bufonis, soak after drying through fresh milk and pulverize with 95% alcohol heating reflux, become Venenum Bufonis dry powder after crossing 40 mesh sieves, standby by the prescription weighing; Last earlier with behind standby Venenum Bufonis dry powder and the abundant mix homogeneously of standby Radix Ginseng total saponins powder again with Spatholobi Paste powder mix homogeneously, No. 1 capsule of packing into gets patent medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB02114687XA CN1205950C (en) | 2002-07-22 | 2002-07-22 | Sanweishenxue capsule for treating aplastic anemia and its preparation technology |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB02114687XA CN1205950C (en) | 2002-07-22 | 2002-07-22 | Sanweishenxue capsule for treating aplastic anemia and its preparation technology |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1413618A CN1413618A (en) | 2003-04-30 |
CN1205950C true CN1205950C (en) | 2005-06-15 |
Family
ID=4743237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB02114687XA Expired - Fee Related CN1205950C (en) | 2002-07-22 | 2002-07-22 | Sanweishenxue capsule for treating aplastic anemia and its preparation technology |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1205950C (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015183545A1 (en) | 2014-05-28 | 2015-12-03 | The Board Of Regents Of The University Of Texas System | Novel compounds supports hematopoietic stem cells and red blood cells |
-
2002
- 2002-07-22 CN CNB02114687XA patent/CN1205950C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1413618A (en) | 2003-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1330347C (en) | Gongbu ointment | |
CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
CN104984297A (en) | Application of pharmaceutical composition in preparation of drugs for treating amenorrhea | |
CN104825963A (en) | Traditional Chinese medicinal preparation for treating habitual abortion, and preparation method thereof | |
CN108653434A (en) | A kind of pharmaceutical composition for treating spleen emptiness and wet sputum type Stein-Leventhal syndrome | |
CN105902827A (en) | Traditional Chinese medicine composition for improving immunity of human body and preparation method thereof | |
CN1762454A (en) | Chinese traditional medicinal composition for treating psoriasis | |
CN105796845A (en) | Application of medicine composition in preparing medicine for treating female climacteric syndromes | |
CN104984296A (en) | Pharmaceutical composition for treating female climacteric syndrome and preparation method thereof | |
CN104644967A (en) | Pharmaceutical composition for treating I-type diabetes and application thereof | |
CN102114189A (en) | Chinese medicinal blood glucose reducing tablet for treating diabetes comprising superfine powder | |
CN111388639B (en) | Phenylethanoid glycoside and isoflavone extract for relieving menopausal syndrome and application thereof | |
CN114344421A (en) | Medicinal and edible pure Chinese herbal medicine composition for treating hypertension and preparation method thereof | |
CN1205950C (en) | Sanweishenxue capsule for treating aplastic anemia and its preparation technology | |
CN108686094B (en) | Traditional Chinese medicine for reducing blood sugar and preparation method thereof | |
CN104984027A (en) | Chinese materia medica preparation for treating myelodysplastic syndrome and preparation method thereof | |
CN105169338A (en) | Medicine composition for treating female climacteric syndromes and preparation method thereof | |
CN1144595C (en) | Anticancer capsule | |
CN103948875A (en) | Medicine for treating hepatitis B and preparation method thereof | |
CN108434274A (en) | A kind of Chinese medicine composition for protect liver | |
CN114796372B (en) | A Chinese medicinal watered pill for treating vitiligo, and its preparation method | |
CN101693096A (en) | Medicament for treating liver cancer and preparation method thereof | |
CN106214910A (en) | A kind of medicine treating dysfunctional uterine bleeding and preparation method thereof | |
CN105412673A (en) | Drug for treating Hashimoto disease and preparing method thereof | |
CN104873854A (en) | Traditional Chinese medicine preparation for rteriolar nephrosclerosis and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |